Cargando…

P01 Antibiotic efficacy treatment of community-acquired pneumonia among CMV-infected individuals

BACKGROUND: The investigation is devoted to possible antibiotic resistance formation and its adverse event prognostic influence among young patients with community-acquired pneumonia (CAP) with cytomegalovirus (CMV) persistence and absence of other comorbid pathology. SUBJECTS AND METHODS: The obser...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chichirelo-Konstantynovych, Kiarina, Konstantynovych, Tetyana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266142/ http://dx.doi.org/10.1093/jacamr/dlad066.005

Ejemplares similares

P16 COVID-19 and urinary tract infection: the main manifestations and their management
por: Chichirelo-Konstantynovych, Kiarina, et al.
Publicado: (2023)

Prognostic influence of toll-like receptor 4 gene polymorphism into community-acquired pneumonia course among young patients with cytomegalovirus persistence
por: Moroz, Larysa V, et al.
Publicado: (2019)

P04 Assessment of antibiotic resistance formation predictors among medical students in developing countries
por: Bondaruk, Iryna, et al.
Publicado: (2023)

Efficacy of maternal vaccination during pregnancy against infant respiratory viruses
por: Tran, Cammie, et al.
Publicado: (2022)

ERS International Congress, Madrid, 2019: highlights from the Respiratory Infections Assembly
por: Calarasu, Cristina, et al.
Publicado: (2020)

ERS International Congress 2022: highlights from the Respiratory Infections Assembly
por: Banka, Radhika, et al.
Publicado: (2023)

ERS International Congress 2021: highlights from the Respiratory Infections Assembly
por: Meldrum, Oliver W., et al.
Publicado: (2022)

O01 Auditing the duration of antibiotic therapy for children treated as inpatients for community acquired pneumonia
por: Alexander, Emma, et al.
Publicado: (2023)

P24 Auditing antibiotic course lengths for the management of community-acquired pneumonia and hospital-acquired pneumonia against current NICE guidance
por: Chua, Elaine, et al.
Publicado: (2023)

519. Longer Length of Antibiotic Therapy for Community-Acquired Pneumonia and Risk of Clostridium difficile Infection
por: Yi, Sarah H, et al.
Publicado: (2018)

1646. Optimizing Antibiotic Durations of Therapy in Pediatric Community-acquired Pneumonia
por: Cook, Gregory, et al.
Publicado: (2023)

879. Intravenous to Oral Antibiotic Switch in Patients Hospitalized with Community-Acquired Pneumonia
por: Deshpande, Abhishek, et al.
Publicado: (2022)

2590. Efficacy of Doxycycline Versus Azithromycin in Community Acquired Pneumonia
por: Mei, Julie, et al.
Publicado: (2023)

Severe cytomegalovirus (CMV) community-acquired pneumonia (CAP) in a nonimmunocompromised host
por: Cunha, Burke A., et al.
Publicado: (2009)

Impact of an Emergency Medicine Pharmacist on Appropriate Empiric Antibiotic Prescribing for Community-Acquired Pneumonia and Intra-Abdominal Infections
por: Kulwicki, Benjamin, et al.
Publicado: (2017)

Use of MRSA Nasal Swab to Guide Empiric Antibiotic Treatment of Hospital Acquired or Community Acquired Pneumonia in a Pediatric Population
por: Linfesty, Daniel, et al.
Publicado: (2017)

Community-Acquired Pneumonia in HIV-Infected Individuals
por: Brown, James, et al.
Publicado: (2014)

2121. The Impact of Donor CMV Serostatus on Outcomes of CMV Infections in the Era of Letermovir
por: Aramburo, Oscar Morado, et al.
Publicado: (2022)

261. Alternative Antibiotic Prescribing for Community Acquired Pneumonia (CAP) in Pediatric Patients in Relation to Allergy Status
por: Desai, Ankita, et al.
Publicado: (2018)

1773. Impact of Antibiotics Used to Treat Community Acquired Pneumonia on the Gut Microbiome and Resistome in Healthy Volunteers
por: Anthony, Winston, et al.
Publicado: (2018)

1666. A Clinical Care Pathway Improves Antibiotic Prescribing in Hospitalized Children with Community Acquired Pneumonia
por: Schweiger, Jennifer, et al.
Publicado: (2023)

1457. Escherichia coli Community Acquired Pneumonia
por: John, Teny Mathew, et al.
Publicado: (2018)

Antibiotic Prescribing for Pediatric Community-Acquired Pneumonia at Children’s Hospitals and General Hospitals Following National Guideline Release
por: Tribble, Alison, et al.
Publicado: (2017)

747. Antibiotic Therapy for Community-Acquired Pneumonia: A Systematic Review and Network Meta-Analysis of Randomized Trials
por: Siemieniuk, Reed, et al.
Publicado: (2018)

1336. Impact of Procalcitonin-Guided Antibiotic Management in Chronic Obstructive Pulmonary Disease Exacerbation and Community-Acquired Pneumonia
por: Triner, Molly, et al.
Publicado: (2019)

2724. Community-acquired Pneumonia in Immunocompromised Patients: Predictors and Outcomes Associated with Empiric Broad-spectrum Antibiotic Treatment
por: Saravolatz, Louis, et al.
Publicado: (2023)

1991. Implementation of Rapid Turnaround PCR Bacterial/Viral Panel Testing in Community-acquired Pneumonia Decreases LOS, Antibiotic Cost, Antibiotic Charges, and Antibiotic Use
por: Shadowen, Rebecca D, et al.
Publicado: (2019)

1538. High Mortality of Cytomegalovirus (CMV) Pneumonia in Hematopietic Cell Transplant Recipients
por: Batista, Marjorie, et al.
Publicado: (2018)

2101. CMV Infections in Multiple Myeloma Patients
por: Ilyas, Sahrish, et al.
Publicado: (2022)

146. Predictors of Long Duration Antibiotic Therapy for Urinary Tract Infections and Community-Acquired Pneumonia in Pediatric Ambulatory Care Settings
por: Shah, Rohan M, et al.
Publicado: (2021)

1139. Multidisciplinary Initiative to Increase Guideline-Concordant Antibiotic Prescriptions at Discharge for Hospitalized Children with Uncomplicated Community-Acquired Pneumonia
por: Yonts, Alexandra B, et al.
Publicado: (2019)

517. Impact of Doxycycline in Place of Azithromycin for Community-Acquired Pneumonia on Clostridium difficile Infections
por: John, Jamie, et al.
Publicado: (2018)

1501. Risk Factors for Clostridium difficile Infection in Patients Hospitalized with Community-Acquired Pneumonia
por: Deshpande, Abhishek, et al.
Publicado: (2019)

P02 Antimicrobial susceptibility of microorganisms isolated in community-acquired pneumonia in drug-dependent patients
por: Viltsaniuk, Oksana, et al.
Publicado: (2023)

Combination antibiotic therapy for community-acquired pneumonia
por: Caballero, Jesus, et al.
Publicado: (2011)

1149. Contribution of S.pneumoniae Serotypes in Adults with Invasive Pneumococcal Disease (IPD) and Pneumococcal Community-acquired Pneumonia (pCAP)
por: Apodaca, Kevin, et al.
Publicado: (2023)

Efficacy and safety of sequential IV/PO moxifloxacin for the treatment of severe community-acquired pneumonia
por: Lode, H, et al.
Publicado: (2002)

Detection of Cytomegalovirus (CMV) in Saliva of Congenitally Infected Neonates
por: Wissel, Mark, et al.
Publicado: (2017)

1198. Measurement of Pre-transplant Anti-cytomegalovirus (CMV) Immunoglobulin G Titer to Predict Risk of CMV Infection in CMV-seropositive Kidney Transplant Recipients
por: Kirisri, Similan, et al.
Publicado: (2020)

2190. Influence of Microbiological Culture Results on Antibiotic Choice for Veterans with Hospital-Acquired Pneumonia
por: Lee Anne. Christian, Robbie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_11t3ovvmc8asc202sm6fs8lc2c